Capital That Understands the Science.
Strategic support for oncology and hematology startups, powered by precision and expertise.
Fueling Oncology Innovation
Caizio Ventures powers oncology and hematology startups with expert investment and hands-on support beyond just funding.
Strategic Support
Investment Focus
From data room prep to clinical introductions, we back founders targeting biotech, medtech, and healthtech sectors.
VERTICAL SPECIALIZATION
Support fueling oncology and hematology startups.
Biotech & Therapeutics
High-conviction bets on next-gen immunotherapies, solid tumor candidates, and hematological molecular discovery.
MedTech & Devices
Precision hardware including smart wearables, diagnostic monitoring tools, and surgical oncology tech.
Software-driven solutions for EHR integration, telemedicine, and AI-powered diagnostics outside the hospital.
HealthTech & Software
FAQs
What is Caizio Ventures?
We invest in oncology and hematology startups with hands-on support.
Do you support medical devices or only therapeutic drugs?
We can help with innovative Biotech therapeutics as well as MedTech devices and HealthTech software platforms, provided they address unmet needs in oncology or hematology.
What investment stages does Caizio Ventures typically target?
We primarily target pre-Seed and Seed rounds. However, through our internal startup studio (Caizio Labs), we often engage with founders at the earliest concept stage to help establish proof-of-concept and technical viability. We also have a network of investors that engage in later stages.
Will you help my startup secure non-dilutive funding like SBIRs?
Yes. Helping founders secure SBIR and BAA grants is a core activity at Caizio Labs, our startup studio. We believe non-dilutive capital is essential for de-risking high-science assets without unnecessary early equity dilution.
What makes your capital different?
Traditional VCs provide capital and occasional advice. As a Venture Studio, we provide 'Hands-on' execution. We partner on product design, prototyping, and regulatory strategy, essentially acting as an extension of your founding team to accelerate technical milestones.
What are the specific 'outside-the-hospital' solutions you look for?
We are highly interested in innovations that manage cancer outside acute care settings, such as remote patient monitoring wearables, AI diagnostics for home screening, and telemedicine platforms tailored for oncology care coordination.